Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose cladribine plus valproic acid in previously treated B-cell chronic lymphocytic leukemia
2010-019983-35Phase 2Terminated
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cladribine and valproic acid in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Cliniques universitaires Saint-Luc. Primary endpoints: Tolerability of valproic acid in combination with low-dose cladribine and Biologically effective dose of valproic acid. Started Aug 2010; status: terminated.
02
Drugs
cladribinevalproic acid
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2010-019983-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019983-35.